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Available online 21 October 2016This prospective uncontrolled study evaluated the effect of low-dose adjunctive perampanel therapy (4 mg/day
for 3 months) on the sleep-wake cycle and daytime somnolence in adult patients (n= 10) with focal seizures. A
N50% reduction in the number of seizureswas reported in 80% of the study patients; treatment had no significant
effect on any sleep parameters as evident by theMaintenance ofWakefulness Test, Pittsburgh SleepQuality Index
and Epworth Sleepiness Scale scores. Two patients reported dizziness with treatment. In conclusion, low-dose
perampanel may improve seizure control without affecting the sleep characteristics or daytime somnolence in
patients with epilepsy.






Maintenance of wakefulness test
Antiepileptic drugs1. Introduction
Perampanel is a non-competitive antagonist of the AMPA receptor
approved for the adjunctive treatment of epilepsy [1]. Data from pivotal
clinical trials and real-life studies show that perampanel causes effective
reduction in the number of seizures [2,3]. However, one of the main
concerns with the use of perampanel is the treatment-associated som-
nolence which is the main reason for the drug being recommended at
bedtime [1].
Sleep architecture and daytime somnolence can be assessed using
different methods. The use of subjective assessments has been reported
in studies with large number of patients; however, objective methods
have shown better reliability [4,5]. Home actigraphy for 1–2 weeks in
combination with the maintenance of wakefulness test (MWT) are the
most commonly used objective methods that are reported to be useful
in determining the effects of a treatment on sleep and daytimeevents; AMPA, α-amino-3-hy-
nervous system; ESS, Epworth
PSQI, Pittsburgh sleep quality






. This is an open access article undersleepiness [6]. These tests serve as low-cost, non-invasive, longitudinal
methods for the diagnostic and post-treatment evaluation of sleep in
ambulatory settings [6]. Polysomnography can also be used to deter-
mine the impact of a treatment on sleep architecture; however the com-
plexity and cost of this assessment limit its use [7].
All anti-seizure drugs (ASDs) have a potential impact on sleep archi-
tecture and daytime somnolence. Studies have suggested that newer
ASDs may have favorable effects on the sleep-wake cycle than the
older ones [8,9]. However, no objective studies have explored the effect
of perampanel on sleep. The present study assessed the impact of ad-
junctive perampanel therapy on the quality of sleep and daytime som-
nolence in patients with epilepsy and evaluated the treatment-
associated AEs.
2. Material and methods
This prospective non-interventional study included patients aged N
16 years whohad epilepsywith focal seizures, were on stable treatment
with ≥1ASD for at least 3 months for which a clinical decision for initi-
ating perampanel therapy was taken. Patients with progressive dis-
eases, major psychiatric disorders, history of non-epileptic seizures,
intake of drugs interfering with the CNS other than ASDs and evidence
of sleep disorders were excluded.
A full anamnesis including the seizure type and frequencies in the
past 3 months was performed at the baseline visit. Further, a pre-
treatment sleep assessment was performed in all patients beforethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patients demographics and baseline clinical characteristics.
Characteristics N = 10 (%)
Age, years (mean ± SD) 40.10 ± 14.6
Male, n (%) 5 (50)
Seizure frequency/month, median (IQR) 2 (1–16)




Seizure etiology, n (%)
Unknown 4 (40)
Mesial temporal sclerosis 2 (20)
Trauma 2 (20)
Malformation of cortical development 1 (10)
Meningitis 1 (10)
Seizure type, n (%)
Simple partial 4 (40)
Complex partial 7 (70)
Secondary generalized 2 (20)
Seizure origin, n (%)
Frontal 4 (40)
Temporal 6 (60)
ASD, anti-seizure drug; IQR: interquartile range; SD, standard deviation.
Table 2
Nocturnal and daytime sleep assessments at baseline and after 3 months of treatment







TST (min) 430.10 ± 63.08 438.70 ± 55.96 0.441
Sleep latency (min) 10.87 ± 8.25 16.03 ± 12.67 0.241
Sleep efficiency (%) 91.36 ± 3.60 89.27 ± 4.91 0.093
PSQI score
Global score 4.10 ± 3.72 3.60 ± 3.89 0.357
Subjective sleep quality 0.80 ± 0.92 0.60 ± 0.70 0.317
Sleep latency 0.90 ± 0.88 0.80 ± 1.23 0.739
Sleep duration 0.70 ± 1.06 0.60 ± 0.84 0.564
Sleep efficiency 0.50 ± 0.97 0.70 ± 1.25 0.317
Sleep disturbances 0.70 ± 0.48 0.50 ± 0.53 0.157
Sleeping medication 0.00 ± 0.00 0.10 ± 0.32 0.317
Daytime dysfunction 0.50 ± 0.70 0.30 ± 0.67 0.157
ESS score 4.70 ± 3.65 3.80 ± 4.21 0.323
MWT (minutes) 24.10 ± 10.72 24.10 ± 11.97 0.799
ESS, Epworth sleepiness scale; MWT, maintenance wakeful test; PSQI, Pittsburgh sleep
quality index; SD, standard deviation; TST, total sleep time.
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Index (PSQI), the Epworth Sleepiness Scale (ESS) and 1week of domicil-
iary actigraphy followed by the MWT. Perampanel was added to base-
line ASDs and given once daily at bedtime with a starting dose of 2 mg
increasing to 4 mg after the first 2 weeks. At the end of 3-month treat-
ment period, all patients on stable-dose perampanel and unchanged
baseline ASD scheme underwent a follow-up which included the same
sleep assessments as at baseline. Any dose adjustment during follow-
up was based on the seizure control and tolerability of perampanel.
The ESS and the PSQI scores were considered normal for values
below 10 and 5, respectively. Actigraphywas performed using a contin-
uous wristwatch like actigraph (Actiwatch MiniMitter) that measured
the 3D movements in the non-dominant limb; data were processed
using the Actiware sleep software version 5.3 (MiniMitter Company)
to determine the sleep latency (first 10-min period with b2 epochs of
activity), sleep time (sumof time of epochs not exceeding the sensitivity
threshold), sleep efficiency (sleep time divided by the time in bed mul-
tiplied by 100), wake after sleep onset (total time awake after the first
sleep onset period) and themovement and fragmentation index (num-
ber of 1-min periods of immobility relative to the total number of im-
mobility phases).
The MWT was performed on the day the patients returned the
actigraph in order to objectively test daytime somnolence and consisted
of four trials performed at 2-h intervals, with the first trial beginning
about 1.5 h after the patient's usual wake-up time. TheMWT recordings
included electroencephalogram derivations (C3-A2, C4-A1, O1-A2 and
O2-A1), electrooculograms, chin electromyogram and electrocardio-
gram. Patients were asked to sit still and remain awake for as long as
possible. Sleep onset was defined as the first epoch of N15 s of cumula-
tive sleep in a 30-s epoch. Trials ended after 40min if no sleep occurred
or after unequivocal sleep, defined as three consecutive epochs of stage
1 sleep, or one epoch of any other stage of sleep. Themean sleep latency
from all sessions and the number of sleep-onset rapid eye movement
(REM) periods during the MWT were calculated for each patient.
The study was approved by the Local Ethics Committee (mat-lev-
2014-01) and all patients included in the study provided a written in-
formed consent.
2.1. Statistical methods
Descriptive and frequency statistical analysis were performed and
comparisons were made using the SPSS Statistics software Version
17.0. Wilcoxon signed ranks test was used to assess changes in the
actigraphy values and the PSQI and ESS scores. A p-value of b0.05 was
considered as statistically significant.
3. Results
Of the 13 patients enrolled in the study, three were excluded due to
discontinuation of perampanel treatment: reasons included insufficient
response in one patient and dizziness in two patients. Baseline demo-
graphics and the clinical data of the patients included in the study are
shown in Table 1.
Perampanel was administered at a dose of 4 mg/day in all patients.
The concomitant ASDs used were oxcarbazepine (n = 3); levetirace-
tam, lacosamide, eslicarbazepine and carbamazepine (n = 2 each);
and phenytoin, lamotrigine, phenobarbital and zonisamide (n = 1
each). At the end of 3-month treatment, eight patients (80%) showed
a seizure reduction of N50%, of which three were seizure-free and two
reported persistent mild dizziness related to perampanel treatment.
No other AEs were reported.
The baseline assessments of nocturnal sleep, actigraphy, PSQI scores
and MWT and ESS scores were within normal limits. Following 3
months of perampanel treatment, no significant changes in sleep as-
sessments were observed (Table 2). MWT was performed at a median
time of 8.5 h (range 8–9.5 h) after the last dose of perampanel duringthe follow-up assessment in all patients. A reduction in each component
of the PSQI scores was observed with treatment; these differences were
not statistically significant (Table 2). No sleep-onset REM periods were
observed before or after treatment.
4. Discussion
The present exploratory study determined the effect of low-dose ad-
junctive perampanel therapy on somnolence and sleep in patients with
epilepsy. Perampanel was well tolerated; no sleep disturbances were
observed nor were there any changes in sleep parameters.
Several studies have explored the effect of ASDs on sleep character-
istics [8,9]. However, data from these studies is not robust due to the un-
controlled nature of these trials. This studywas based on an exploratory
approach focused to understand the impact of perampanel on the qual-
ity of sleep and daytime somnolence in patients with epilepsy. Treat-
ment reduced the number of seizures with no significant
modifications in the objective and subjective assessments of the quality
of sleep and somnolence.
Perampanel is recommended at bedtime due to a potential risk of
somnolence [1,10,11]. Additional risk factors associated with increased
daytime somnolence in patients with epilepsy are ASD polytherapy
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dependent AE reported in 12–18% of patients taking perampanel [3,
13]. Also, daytime somnolence is reported in 11–28% of patients with
focal epilepsy [12]. The results of this study did not show any effect of
perampanel on the sleep latency; this may be due to the fact that the
study included patients with healthy sleep characteristics with no sig-
nificant somnolence at baseline and used lower doses of perampanel
than reported in pivotal studies [2] along with a high rate of seizure re-
sponders observed in the study, whichmay have introduced bias in the
results.
The prospective data evaluation during this exploratory study and
the use of combined objective and subjective tests carried at a single
center are the major strengths of the study. Conversely, the open-
label, uncontrolled study design and the small sample size are the
main limitations. Also, the MWT was performed long after perampanel
intake; it would be interesting to perform the test immediately after
perampanel intake to confirm the peak-of-dose somnolence effect of
the drug. The use of polysomnography could also have provided infor-
mation on the impact of perampanel treatment on sleep architecture.
The present study was based on the hypothesis that low-dose
perampanel may have a beneficial effect on the sleep patterns of pa-
tients with epilepsy. However, due to the relatively short duration of
the study and healthy sleep profile of the study population, the results
do not support the initial hypothesis.
5. Conclusion
The present study suggests that low-dose adjunctive perampanel
therapy in patients with epilepsy may improve the control of seizures
without affecting their sleep characteristics or causing daytime sleepi-
ness. Further randomized, placebo-controlled studies with multiple
treatment groups to study the collateral effects of ASDs are warranted.
Conflicts of interest
MGC, MT, ES and XS have received funding and honoraria from Eisai
Pharmaceuticals, UCB Pharma, BIAL, GSK and Esteve.
Funding
This work was supported by Eisai Pharmaceuticals, Spain.Acknowledgements
The authors thank Nishad Parkar, PhD, of Springer Healthcare Com-
munications for providing assistance in English editing and preparing
the manuscript for submission. This assistance was funded by Eisai
Pharmaceuticals, Spain.References
[1] Fycompa: Summary of Product Characteristics [database on the Internet] 2012 [cited
28 June 2016]. Available from: http://www.ema.europa.eu/docs/en_GB/document_
library/EPAR_-_Product_Information/human/002434/WC500130815.pdf.
[2] Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, et al. Efficacy
and safety of adjunctive perampanel for the treatment of refractory partial seizures:
A pooled analysis of three phase III studies. Epilepsia 2013;54:1481–9.
[3] Steinhoff BJ, Hamer H, Trinka E, Schulze-Bonhage A, Bien C, Mayer T, et al. A multi-
center survey of clinical experiences with perampanel in real life in Germany and
Austria. Epilepsy Res 2014;108:986–8.
[4] Foldvary-Schaefer N, Grigg-Damberger M. Sleep and epilepsy: What we know, don't
know, and need to know. J Clin Neurophysiol 2006;23:4–20.
[5] Jain SV, Glauser TA. Effects of epilepsy treatments on sleep architecture and daytime
sleepiness: An evidence-based review of objective sleep metrics. Epilepsia 2014;55:
26–37.
[6] American Sleep Disorders Association. Practice parameters for the use of actigraphy
in the clinical assessment of sleep disorders. Sleep 1995;18:285–7.
[7] Bourne RS, Minelli C, Mills GH, Kandler R. Clinical review: Sleep measurement in
critical care patients: Research and clinical implications. Crit Care 2007;11:226.
[8] Bazil CW. Effects of antiepileptic drugs on sleep structure: Are all drugs equal? CNS
Drugs 2003;17:719–28.
[9] Legros B, Bazil CW. Effects of antiepileptic drugs on sleep architecture: A pilot study.
Sleep Med 2003;4:51–5.
[10] Krauss GL. Perampanel: A selective AMPA antagonist for treating seizures. Epilepsy
Curr 2013;13:269–72.
[11] Kramer LD, Satlin A, Krauss GL, French J, Perucca E, Ben-Menachem E, et al.
Perampanel for adjunctive treatment of partial-onset seizures: A pooled dose-
response analysis of phase III studies. Epilepsia 2014;55:423–31.
[12] Manni R, Ratti MT, Galimberti CA, Morini R, Perucca E, Tartara A. Daytime sleepiness
in epileptic patients on long-term monotherapy: MSLT, clinical and psychometric
assessment. Neurophysiol Clin 1993;23:71–6.
[13] Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Clement JF, et al. Long-term
safety of perampanel and seizure outcomes in refractory partial-onset seizures and
secondarily generalized seizures: Results from phase III extension study 307.
Epilepsia 2014;55:1058–68.
